• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.

作者信息

Gaspari Valeria, Zengarini Corrado, Greco Sonia, Vangeli Valeria, Mastroianni Antonio

机构信息

Unit of Dermatology, Head and Neck Department, St. Orsola Malpighi University Hospital, Bologna, Italy.

Unit of Infectious and Tropical Diseases, SS Annunziata Hospital, Cosenza, Italy.

出版信息

Int J Antimicrob Agents. 2020 Aug;56(2):106023. doi: 10.1016/j.ijantimicag.2020.106023. Epub 2020 May 22.

DOI:10.1016/j.ijantimicag.2020.106023
PMID:32450201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7243754/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5750/7243754/c8b9a6df090a/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5750/7243754/c8b9a6df090a/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5750/7243754/c8b9a6df090a/gr1_lrg.jpg

相似文献

1
Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.芦可替尼治疗新型冠状病毒肺炎患者的不良反应：2例病例报告
Int J Antimicrob Agents. 2020 Aug;56(2):106023. doi: 10.1016/j.ijantimicag.2020.106023. Epub 2020 May 22.
2
Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.托珠单抗治疗严重急性呼吸综合征冠状病毒2型肺炎的安全性和有效性：一项回顾性队列研究。
Indian J Med Microbiol. 2020 Jan-Mar;38(1):117-123. doi: 10.4103/ijmm.IJMM_20_298.
3
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?芦可替尼对有急性呼吸窘迫综合征（ARDS）风险的新型冠状病毒肺炎（COVID-19）感染患者是否有效？
Ann Hematol. 2020 Jul;99(7):1675-1676. doi: 10.1007/s00277-020-04067-6. Epub 2020 May 14.
4
Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.新型冠状病毒肺炎的新兴治疗方法：包括药物过敏在内的药物不良反应。
J Allergy Clin Immunol. 2020 Oct;146(4):786-789. doi: 10.1016/j.jaci.2020.07.008. Epub 2020 Jul 22.
5
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.芦可替尼治疗的异基因造血干细胞移植患者中新型 SARS-CoV-2 感染减弱。
Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):720-723. doi: 10.1016/j.clml.2020.06.014. Epub 2020 Jun 25.
6
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼可能对新冠病毒感染患者的肺损伤具有保护作用。
Blood. 2020 May 21;135(21):1912-1915. doi: 10.1182/blood.2020006288.
7
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.芦可替尼通过 JAK/STAT 通路抑制在 COVID-19 治疗中的潜力。
Cytokine Growth Factor Rev. 2020 Aug;54:51-62. doi: 10.1016/j.cytogfr.2020.06.013. Epub 2020 Jun 20.
8
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.芦可替尼治疗严重 2019 冠状病毒病（COVID-19）：一项多中心、单盲、随机对照试验。
J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3. doi: 10.1016/j.jaci.2020.05.019. Epub 2020 May 26.
9
Tocilizumab administration in a refractory case of COVID-19.托珠单抗在一例难治性新型冠状病毒肺炎病例中的应用
Int J Antimicrob Agents. 2020 Aug;56(2):106043. doi: 10.1016/j.ijantimicag.2020.106043. Epub 2020 Jun 2.
10
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).芦可替尼用于治疗新型冠状病毒肺炎引发的急性呼吸窘迫综合征（ARDS）。
Leukemia. 2020 Aug;34(8):2276-2278. doi: 10.1038/s41375-020-0907-9. Epub 2020 Jun 17.

引用本文的文献

1
Nanotherapy therapy for acute respiratory distress syndrome: a review.纳米疗法治疗急性呼吸窘迫综合征：综述
Front Med (Lausanne). 2024 Dec 6;11:1492007. doi: 10.3389/fmed.2024.1492007. eCollection 2024.
2
Novel insights into the ROCK-JAK-STAT signaling pathway in upper respiratory tract infections and neurodegenerative diseases.对上呼吸道感染和神经退行性疾病中ROCK-JAK-STAT信号通路的新见解。
Mol Ther. 2025 Jan 8;33(1):32-50. doi: 10.1016/j.ymthe.2024.11.011. Epub 2024 Nov 7.
3
Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives.

本文引用的文献

1
Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.探讨衰老治疗学对于当前 SARS-CoV-2 紧急情况和类似未来全球健康威胁的相关性。
Cells. 2020 Apr 8;9(4):909. doi: 10.3390/cells9040909.
2
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.严重 COVID-19 中的细胞因子释放综合征：白细胞介素-6 受体拮抗剂托珠单抗可能是降低死亡率的关键。
Int J Antimicrob Agents. 2020 May;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954. Epub 2020 Mar 29.
3
COVID-19: combining antiviral and anti-inflammatory treatments.
间充质干细胞/基质细胞治疗 COVID-19 肺炎：潜在机制、当前临床证据和未来展望。
Stem Cell Res Ther. 2022 Mar 24;13(1):124. doi: 10.1186/s13287-022-02810-6.
4
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).白细胞介素 6 信号阻断在严重 2019 年冠状病毒病（COVID-19）中的最新进展、挑战和临床考虑的更新概述。
Int Immunopharmacol. 2022 Apr;105:108536. doi: 10.1016/j.intimp.2022.108536. Epub 2022 Jan 11.
5
The JAK/STAT signaling pathway: from bench to clinic.JAK/STAT 信号通路：从基础到临床。
Signal Transduct Target Ther. 2021 Nov 26;6(1):402. doi: 10.1038/s41392-021-00791-1.
6
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues.Janus激酶抑制剂与冠状病毒病（COVID）-19：理论依据、临床证据及安全性问题
Pharmaceuticals (Basel). 2021 Jul 28;14(8):738. doi: 10.3390/ph14080738.
7
JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy.芦可替尼对新型冠状病毒肺炎合并重症肺炎患者的JAK抑制作用：来自意大利一项同情用药计划的多中心临床经验
J Clin Med. 2021 Aug 23;10(16):3752. doi: 10.3390/jcm10163752.
8
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.细胞因子风暴和I型干扰素反应在新冠病毒疾病发病机制中的关键决定因素
Clin Microbiol Rev. 2021 May 12;34(3). doi: 10.1128/CMR.00299-20. Print 2021 Jun 16.
9
Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19.平息风暴：天然免疫抑制剂作为辅助手段靶向新冠病毒肺炎中的细胞因子风暴
Front Pharmacol. 2021 Jan 27;11:583777. doi: 10.3389/fphar.2020.583777. eCollection 2020.
10
Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?衰老、免疫与2019冠状病毒病：年龄如何影响宿主对冠状病毒感染的免疫反应？
Front Physiol. 2021 Jan 12;11:571416. doi: 10.3389/fphys.2020.571416. eCollection 2020.
2019冠状病毒病：联合抗病毒与抗炎治疗
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
4
Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.在临床实践中管理JAK抑制剂治疗骨髓纤维化的副作用。
Expert Rev Hematol. 2017 Jul;10(7):617-625. doi: 10.1080/17474086.2017.1337507. Epub 2017 Jun 19.
5
The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.CYP3A4 抑制或诱导对健康志愿者口服 ruxolitinib（磷酸 INCB018424）的药代动力学和药效学的影响。
J Clin Pharmacol. 2012 Jun;52(6):809-18. doi: 10.1177/0091270011405663. Epub 2011 May 20.